1. Home
  2. PRTC vs EAD Comparison

PRTC vs EAD Comparison

Compare PRTC & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • EAD
  • Stock Information
  • Founded
  • PRTC 2015
  • EAD 2003
  • Country
  • PRTC United States
  • EAD United States
  • Employees
  • PRTC N/A
  • EAD N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • EAD Finance/Investors Services
  • Sector
  • PRTC Health Care
  • EAD Finance
  • Exchange
  • PRTC Nasdaq
  • EAD Nasdaq
  • Market Cap
  • PRTC 439.8M
  • EAD 406.6M
  • IPO Year
  • PRTC N/A
  • EAD N/A
  • Fundamental
  • Price
  • PRTC N/A
  • EAD $7.04
  • Analyst Decision
  • PRTC Buy
  • EAD
  • Analyst Count
  • PRTC 1
  • EAD 0
  • Target Price
  • PRTC $45.00
  • EAD N/A
  • AVG Volume (30 Days)
  • PRTC 5.9K
  • EAD 178.9K
  • Earning Date
  • PRTC 08-27-2025
  • EAD 01-01-0001
  • Dividend Yield
  • PRTC N/A
  • EAD 8.91%
  • EPS Growth
  • PRTC N/A
  • EAD N/A
  • EPS
  • PRTC 0.21
  • EAD N/A
  • Revenue
  • PRTC $4,828,000.00
  • EAD N/A
  • Revenue This Year
  • PRTC $35.98
  • EAD N/A
  • Revenue Next Year
  • PRTC $115.38
  • EAD N/A
  • P/E Ratio
  • PRTC $7.93
  • EAD N/A
  • Revenue Growth
  • PRTC 44.98
  • EAD N/A
  • 52 Week Low
  • PRTC $13.30
  • EAD $5.69
  • 52 Week High
  • PRTC $25.00
  • EAD $6.81
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 43.39
  • EAD 78.09
  • Support Level
  • PRTC $16.50
  • EAD $6.83
  • Resistance Level
  • PRTC $18.40
  • EAD $7.18
  • Average True Range (ATR)
  • PRTC 0.45
  • EAD 0.04
  • MACD
  • PRTC -0.17
  • EAD 0.02
  • Stochastic Oscillator
  • PRTC 20.88
  • EAD 90.00

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

Share on Social Networks: